Todd Chappell, who serves as the Chief Operating Officer at Korro Bio, Inc. (NASDAQ: KRRO), completed a mandatory sale of 3,168 shares of the company's common stock on June 16, 2026. According to a recent Securities and Exchange Commission (SEC) filing, the transaction resulted in proceeds of $34,309. The shares were liquidated at prices ranging between $10.58 and $11.35 per share, establishing a weighted-average sale price of $10.83. This transaction was not discretionary but rather a mandatory execution to satisfy tax withholding obligations incurred when restricted stock units (RSUs) vested and settled under the company's 2023 Stock Option and Incentive Plan.
Following this transaction, Mr. Chappell directly holds 16,966 shares of Korro Bio common stock. This total includes 10,066 shares of common stock issuable upon the settlement of a restricted stock unit, which is scheduled to vest on December 15, 2026, provided the reporting person maintains a continuous service relationship with the company through that date. The stock has shown strong momentum recently, posting a 35% return over the past six months.
Key Points
- Todd Chappell sold 3,168 shares for $34,309 to cover tax obligations from vesting RSUs.
- Korro Bio announced KRRO-111, a treatment candidate for alpha-1 antitrypsin deficiency (AATD), using GalNAc-conjugated oligonucleotide technology.
- Analysts Jones Trading and H.C. Wainwright have adjusted their price targets and ratings for KRRO, citing pipeline progress.
Risks and Uncertainties
- The vesting of 10,066 additional shares in December 2026 is contingent on Chappell maintaining continuous service with the company.
- The regulatory filing for KRRO-121, aimed at treating hyperammonemia in urea cycle disorders and hepatic encephalopathy, is scheduled for the latter half of 2026, introducing execution risk for the company's lead program.
- The stock's recent 35% return over six months may indicate heightened volatility, requiring careful monitoring of valuation metrics.
Analyst and Pipeline Developments
In other recent news, Korro Bio Inc. has made significant updates to its pipeline and garnered attention from analysts. The company announced the addition of KRRO-111, a treatment candidate for alpha-1 antitrypsin deficiency (AATD), which utilizes a GalNAc-conjugated oligonucleotide to address a genetic variant and restore normal protein production. This development has caught the attention of Jones Trading, which upgraded Korro Bio's stock rating from Hold to Buy, setting a new price target of $23.00. The upgrade comes in light of promising preclinical data showing significant improvements in RNA editing for AATD treatment.
Additionally, H.C. Wainwright adjusted its price target for Korro Bio to $15 from $20, maintaining a Buy rating on the stock. The firm noted that Korro Bio's lead program, KRRO-121, aimed at treating hyperammonemia in urea cycle disorders and hepatic encephalopathy, remains on schedule for a regulatory filing in the latter half of 2026. Korro Bio has also shared updates on its GalNAc-conjugated AATD program at the American Society of Gene & Cell Therapy (ASGCT). These recent developments highlight the company's ongoing efforts and potential in advancing its treatment pipeline.
According to InvestingPro analysis, the stock appears undervalued at current levels, with 9 additional ProTips available to subscribers. The stock closed at $11.05, up $0.39 or 3.66% during regular trading hours on June 16, 2026. Following this transaction, Mr. Chappell directly holds 16,966 shares of Korro Bio common stock. This total includes 10,066 shares of common stock issuable upon the settlement of a restricted stock unit, which is scheduled to vest on December 15, 2026, provided the reporting person maintains a continuous service relationship with the company through that date. The stock has shown strong momentum recently, posting a 35% return over the past six months.